Habib Syed S, Aslam Muhammad, Naveed Abdul K, Razi Muhammad S
Department of Physiology, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Saudi Med J. 2006 Feb;27(2):174-80.
The aim of this study is to compare lipid and lipoprotein (a) profiles in patients with type 2 diabetes mellitus (DM) on insulin and oral hypoglycemic therapy.
The study took place in the Department of Physiology, Army Medical College, Rawalpindi, Pakistan, during 2002. Ninety-seven type 2 DM patients participated in the study. We divided the patients according to the type of treatment into sulphonylurea (n=40), sulphonylurea plus metformin (n=33) and insulin (n=24) therapy groups as well as 40 healthy subjects served as controls. Fasting blood samples were analyzed for lipoprotein (a) [Lp (a)], total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), glucose, glycosylated hemoglobin (HbA1c) and insulin.
Different groups of diabetic patients showed elevated fasting blood glucose (FPG) levels (p<0.0001 for all), HbA1c (p<0.0001 for all) compared with controls. Meanwhile, fasting insulin levels were elevated only in insulin treated group compared with oral hypoglycemic treated groups and controls (p<0.0001 for all). Patients on sulphonylurea and on sulphonylurea plus metformin groups showed significantly elevated TC (p<0.001, p<0.0001), TG (p<0.001, p<0.01), LDL-C (p<0.01, p<0.001) and LDL-C/HDL-C (p<0.0001, p<0.0001) compared with controls. Insulin therapy group showed significantly decreased TC, TG, LDL-C, LDL-C/HDL-C levels compared with sulphonylurea and sulphonylurea plus metformin treated groups, however, no significant difference was noted in the levels of above mentioned parameters and controls. Meanwhile, HDL-C levels were significantly lower in all diabetic groups compared with controls and were higher in insulin treated group compared with sulphonylurea plus metformin therapy group (p<0.05). Lipoprotein (a) levels were significantly higher in different diabetic groups compared with controls. While there was a non-significant difference in Lp (a) levels between different diabetic groups.
Patients with type 2 DM who are being treated on insulin have a better lipid profile (TC, HDL-C, LDL-C, TG) compared with those patients on oral hypoglycemic agents. Meanwhile, Lp (a) levels were raised in all diabetic patients and seem not to be affected either by insulin or by oral hypoglycemic treatment.
本研究旨在比较接受胰岛素和口服降糖治疗的2型糖尿病(DM)患者的血脂和脂蛋白(a)谱。
该研究于2002年在巴基斯坦拉瓦尔品第陆军医学院生理学系进行。97名2型DM患者参与了研究。我们根据治疗类型将患者分为磺脲类(n = 40)、磺脲类加二甲双胍(n = 33)和胰岛素(n = 24)治疗组,以及40名健康受试者作为对照组。对空腹血样进行脂蛋白(a)[Lp(a)]、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、葡萄糖、糖化血红蛋白(HbA1c)和胰岛素分析。
与对照组相比,不同组的糖尿病患者空腹血糖(FPG)水平升高(所有p < 0.0001),HbA1c升高(所有p < 0.0001)。同时,与口服降糖治疗组和对照组相比,仅胰岛素治疗组的空腹胰岛素水平升高(所有p < 0.0001)。与对照组相比,磺脲类和磺脲类加二甲双胍组的患者TC(p < 0.001,p < 0.0001)、TG(p < 0.001,p < 0.01)、LDL-C(p < 0.01,p < 0.001)和LDL-C/HDL-C(p < 0.0001,p < 0.0001)显著升高。与磺脲类和磺脲类加二甲双胍治疗组相比,胰岛素治疗组的TC、TG、LDL-C、LDL-C/HDL-C水平显著降低,然而,上述参数水平与对照组之间无显著差异。同时,与对照组相比,所有糖尿病组的HDL-C水平显著降低,与磺脲类加二甲双胍治疗组相比,胰岛素治疗组的HDL-C水平更高(p < 0.05)。与对照组相比,不同糖尿病组的脂蛋白(a)水平显著更高。不同糖尿病组之间的Lp(a)水平无显著差异。
与口服降糖药治疗的患者相比,接受胰岛素治疗的2型DM患者的血脂谱(TC、HDL-C、LDL-C、TG)更好。同时,所有糖尿病患者的Lp(a)水平均升高,似乎不受胰岛素或口服降糖治疗的影响。